Price to earnings forward of Certara, Inc. – HAM:700
This article provides the "Price to earnings forward" value for Certara, Inc. (HAM:700) on the Hamburg Stock Exchange. It includes details about the period, value, and change, noting that the data is provided by FactSet Research Systems Inc.
Price to sales forward of Certara, Inc. – HAM:700
This article provides financial information for Certara, Inc. (HAM:700), specifically focusing on its Price to Sales forward metric. The content highlights the company's stock exchange listing on the Hamburg Stock Exchange and indicates that no recent trades have occurred.
Enterprise value to revenue forward of Certara, Inc. – NASDAQ:CERT
This article provides financial information for Certara, Inc. (NASDAQ: CERT), focusing on its enterprise value to revenue forward. The content appears to be a stub or a section of a larger financial data report, likely from TradingView, given the source and formatting. It details the company's stock market listing and offers various navigational and informational links related to finance and trading tools.
Enterprise value to revenue forward of Certara, Inc. – HAM:700
This article provides a brief mention of Certara, Inc.'s enterprise value to revenue forward, listed on the Hamburg Stock Exchange under the ticker HAM:700. It appears to be a stub or a section within a larger financial data platform, indicating the company's financial overview is available. The content primarily lists navigation and footer information rather than detailed financial analysis.
Does Certara (CERT) Joining the Russell 2000 Recast Its Biosimulation Investment Narrative?
Certara, Inc. (CERT) has been reclassified into the Russell 2000 index, indicating a shift towards smaller-cap status, while also launching its Bio Venture Catalyst for early-stage biotechs and announcing a CFO transition. This article examines how the index change, coupled with new product offerings, influences Certara's investment narrative focused on biosimulation and model-informed drug development. Despite potential increased trading volatility and customer budget caution, the Bio Venture Catalyst is seen as a key development that could diversify revenue, although analysts remain cautious about future revenue and earnings given recent losses.
Should You Investigate Certara, Inc. (NASDAQ:CERT) At US$6.36?
This article evaluates whether Certara, Inc. (NASDAQ:CERT) is a worthwhile investment at its current price of US$6.36. It likely delves into the company's financials, market position, and future prospects to help potential investors make an informed decision.
Certara, Inc.(NasdaqGS: CERT) added to Russell 2000 Index
Certara, Inc. (NasdaqGS: CERT), a provider of biosimulation software and services, has been added to the Russell 2000 Index. This inclusion means the company's stock will now be part of this widely recognized small-cap index, potentially increasing its visibility and liquidity. The announcement occurred on June 29, 2026, at 02:55 pm EDT.
Enterprise value to EBITDA forward of Certara, Inc. – NASDAQ:CERT
This article displays the "Enterprise value to EBITDA forward" for Certara, Inc. (NASDAQ: CERT) on TradingView. It provides financial data for the company within the Technology Services sector. The page highlights market information, with various disclaimers regarding data providers and copyrights.
Enterprise value to EBIT forward of Certara, Inc. – NASDAQ:CERT
This article provides financial data for Certara, Inc. (NASDAQ: CERT), specifically focusing on its enterprise value to EBIT forward metric. It also lists general information about the company on TradingView, including market data, news, and community features.
Price to book forward of Certara, Inc. – NASDAQ:CERT
The article displays the "Price to book forward" metric for Certara, Inc. (NASDAQ: CERT). It appears to be a financial data point provided by TradingView, with data sourced from ICE Data Services and FactSet Research Systems Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz LLP is investigating Certara, Inc. (NASDAQ: CERT) on behalf of its investors for potential securities fraud or unlawful business practices. This investigation follows a 19% stock price drop after Certara reported a decline in services revenue and bookings in Q1 2026, and an additional 8.13% drop upon the announcement of its CFO's resignation. Investors are encouraged to contact Pomerantz LLP to join the class action.
Certara, Inc. Actuals & Estimates (NASDAQ:CERT)
This article provides an overview of Certara, Inc. (NASDAQ:CERT) stock, including current price, historical performance, analyst forecasts, and financial data. It details information such as market capitalization, earnings reports, revenue, net income, and volatility, while also covering frequently asked questions about the company's financials and investment potential.
CERT Forecast — Price Target — Prediction for 2027
Certara, Inc. (CERT) has a current stock price of 5.44 USD, showing a slight increase in the past 24 hours but a significant decrease over the last year. Analysts have provided a price target range of 6.00 USD to 10.00 USD for the future. The company is set to release its next earnings report on August 11, 2026.
CERT Stock Slides As Certara Faces Probes And CFO Exit
Certara Inc. (CERT) stock is down 7.13% due to weak Q1 2026 services results, including a decline in revenue and bookings, leading to a planned exit from its regulatory services business. Multiple shareholder-rights firms have launched investigations into potential securities-law issues, and CFO John Gallagher is resigning, with Faiz Mohammed appointed as interim CFO. Despite moderate leverage and positive free cash flow, the negative news and technical analysis suggest avoiding the stock for long positions.
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc.
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Certara, Inc. (NASDAQ: CERT) regarding possible violations of federal securities laws and unlawful business practices. This investigation follows Certara's Q1 2026 financial results, which showed a decline in services revenue and bookings, leading to a significant drop in its stock price. Investors who suffered losses are encouraged to contact the firm.
(CERT) Volatility Zones as Tactical Triggers
This article provides an AI-driven stock analysis for Certara Inc. (NASDAQ: CERT), highlighting a positive near-term sentiment with a mid-channel oscillation pattern. It presents an exceptional 73.0:1 risk-reward setup targeting a 27.8% gain versus 0.4% risk. The analysis includes three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones for various time horizons.
Certara Appoints Interim CFO Amid Leadership Transition
Certara announced that its CFO, John E. Gallagher III, resigned effective July 14, 2026, to pursue another opportunity. The company has appointed Faiz Mohammed, its Senior Vice President of Finance and Treasurer, as interim CFO starting July 15, 2026, and reaffirmed its full-year 2026 financial guidance. Analysts currently rate Certara stock (CERT) with a "Buy" rating and an $8.00 price target.
Certara, Inc. Shareholders Are Encouraged to Reach Out to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT) due to recent events including a decline in services revenue and bookings, mixed performance, and the announcement of a CFO transition. The law firm is investigating whether Certara complied with federal securities laws following these developments that impacted the stock price. Investors who suffered losses are encouraged to join the investigation.
CFO steps down at Main Line firm Certara
Certara's CFO, John Gallagher, is resigning from the Main Line firm. This transition follows a recent leadership change in January and the sale of a business unit for up to $135 million. The article was written by John George of the Philadelphia Business Journal.
Certara CFO John Gallagher to resign, reaffirms 2026 guidance
Certara, Inc. announced that its Chief Financial Officer, John Gallagher, will resign effective July 14, 2026. Faiz Mohammed, the current Senior Vice President of Finance and Treasurer, will serve as interim CFO. The company reaffirmed its 2026 financial guidance despite missing Q1 2026 EPS forecasts, and its stock surged after the announcement, with InvestingPro analysis suggesting it is currently undervalued.
Certara Announces CFO Transition
Certara, Inc. (Nasdaq: CERT) announced that its Chief Financial Officer, John Gallagher, will resign effective July 14, 2026. Faiz Mohammed, the company's Senior Vice President of Finance and Treasurer, will serve as Interim CFO while a search for a permanent successor is conducted. Certara also reaffirmed its 2026 financial guidance.
CFO transition at Certara (NASDAQ: CERT) as company reaffirms 2026 guidance
Certara, Inc. (NASDAQ: CERT) announced a CFO transition with John E. Gallagher III resigning to pursue another opportunity, effective July 14, 2026. Faiz Mohammed, Senior Vice President, Finance and Treasurer, will serve as Interim Chief Financial Officer starting July 15, 2026. The company reaffirmed its full-year 2026 financial guidance, noting that Gallagher's departure was not due to any disagreement with management, the board, or its operations or financial reporting.
Certara names interim CFO as John Gallagher plans July exit
Certara announced that CFO John Gallagher plans to resign from his position on July 14, 2026. Faiz Mohammed, the current Senior Vice President of Finance and Treasurer, will serve as interim CFO while the company conducts a search for a permanent successor. Certara also reaffirmed its 2026 financial guidance despite the leadership change.
Certara (CERT) CFO John Gallagher to Resign in 2026, Interim Successor Named
Certara Inc. (CERT) announced that CFO John Gallagher will resign effective July 14, 2026, with Faiz Mohammed appointed as interim CFO during the search for a permanent replacement. The company, which specializes in drug development biosimulation, has a market cap of $938.06 million and a GF Score of 57/100, indicating moderate performance with challenges in profitability despite its key role in the healthcare sector. Investors are advised to consider these factors as the company navigates this leadership transition.
Certara (CERT) CFO John Gallagher to Resign in 2026, Interim Successor Named
Certara Inc (CERT) announced that CFO John Gallagher will resign effective July 14, 2026, with Faiz Mohammed stepping in as interim CFO. The company is actively searching for a permanent replacement. Certara, a healthcare technology firm specializing in drug development biosimulation, faces challenges in profitability and growth, indicated by its negative EPS and a GF Score™ of 57/100.
Certara Announces CFO Transition
Certara, Inc. (Nasdaq: CERT) announced that its Chief Financial Officer, John Gallagher, will resign effective July 14, 2026. Faiz Mohammed, the Senior Vice President of Finance and Treasurer, will serve as Interim CFO. The company has initiated a search for a permanent successor and reaffirmed its 2026 financial guidance.
CERT Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Certara Inc.'s (CERT) financial performance, focusing on its profitability margins and comparing them to competitors MRLN and MOMO. Certara maintains a gross margin of 47.43%, with an operating margin of 4.75% and a net margin of -8.20%, alongside a Return on Equity (ROE) of -1.44%. The company has a market capitalization of $808.94M.
Certara outlines AI push, cost cuts and new growth engines at Jefferies conference
Certara outlined its strategic initiatives at the Jefferies Healthcare Conference, focusing on leveraging AI to accelerate drug development. The company plans to implement cost reduction measures and explore new growth engines to enhance its financial performance and market position. This proactive approach aims to drive innovation and efficiency within the pharmaceutical industry.
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors for potential securities law violations. This investigation follows a 19% drop in Certara's share price after the company reported a decline in services revenues and bookings in its Q1 2026 financial results, which it attributed to "softer performance from Tier 1 customers in MIDD services." Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Certara, Inc. (NASDAQ: CERT) for potential securities law violations after the company reported a decline in Q1 2026 services revenues and bookings, attributing it to "softer performance from Tier 1 customers in MIDD services." This news led to a 19% drop in Certara's shares. The firm encourages shareholders who experienced losses to participate in the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz LLP is investigating potential securities fraud claims against Certara, Inc. (NASDAQ: CERT) after the company reported a decline in services revenue and bookings in Q1 2026 and announced its exit from the regulatory business in its service segment. Following this news, Certara's stock price dropped significantly. The law firm is advising affected investors to contact them regarding a possible class action lawsuit.
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Certara, Inc. (NASDAQ: CERT) for potential securities law violations after the company reported a significant decline in Q1 2026 services revenues and bookings, leading to a 19% stock drop. The firm is encouraging investors who suffered losses to participate in their fraud investigation.
Price-Driven Insight from (CERT) for Rule-Based Strategy
This article provides a price-driven analysis for Certara Inc. (NASDAQ: CERT), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
Certara executives, led by new CEO Jon Resnick, discussed strategic realignment, AI initiatives, and cost priorities at the Jefferies’ 2026 Global Healthcare Conference. The company is reorganizing around two growth engines, ACE and MID3, to improve clinical trial efficiency and leverage computational biology. Certara is also integrating AI into its products and internal operations while pursuing cost reductions and focusing on organic growth over immediate M&A.
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
Certara outlined its strategic realignment, artificial intelligence initiatives, and cost priorities at the Jefferies 2026 Global Healthcare Conference. The company is reorganizing around two growth engines, ACE (accelerating clinical evidence) and MID3 (model-informed drug development and discovery), and integrating AI into its products and internal operations to drive productivity. Certara also aims for $10 million in cost reductions while maintaining R&D investment and focusing on scientist-led sales engagement.
Certara Inc stock (US1567671046): Shares under pressure after investigation headlines
Certara Inc (CERT) shares have been under pressure after a US law firm announced an investigation into potential securities law violations. The investigation, initiated by Bronstein, Gewirtz & Grossman, focuses on allegations related to the company's disclosures, leading to a significant drop in Certara's share price on May 11, 2026. This has prompted investors to re-evaluate the company's valuation and risk profile in the context of other US healthcare software names.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Certara, Inc. (CERT) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Certara, Inc. (NASDAQ:CERT) following a significant drop in its stock price. This decline occurred after Certara reported a year-over-year decrease in services revenue and bookings for Q1 2026 and announced its exit from the regulatory business in its service segment. The firm encourages Certara investors aware of relevant facts or who purchased securities to join the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz LLP is investigating potential securities fraud claims against Certara, Inc. (NASDAQ: CERT) after the company reported "softer performance from Tier 1 customers in MIDD services" and "mixed" services performance, leading to a 19% stock price drop. Investors are encouraged to contact the firm for more information regarding joining a potential class action lawsuit.
Do Options Traders Know Something About Certara Stock We Don't?
This article examines unusual options trading activity in Certara (NASDAQ:CERT) stock, noting larger than typical volumes for both call and put options. It highlights that this surge in activity could indicate an upcoming key event or a change in investor sentiment, as institutional money often signals market moves through such trades. The article suggests that investors should investigate this activity further to understand its potential implications for Certara's stock price.
CERT Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Certara Inc (CERT), indicating a Neutral overall consensus as of June 3, 2026. It details various technical indicators such as RSI, MACD, and moving averages, along with key support and resistance levels. The analysis suggests a mixed outlook with both buy and sell signals from different metrics.
Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Certara, Inc. (CERT) following a significant stock price drop on May 11, 2026. This decline occurred after Certara reported a 4% year-over-year decrease in services revenue and a 14% decline in services bookings for Q1 2026, along with an announcement of exiting its regulatory business. The firm is encouraging investors who purchased Certara securities to contact them to learn more about the investigation and potential claims.
Do Options Traders Know Something About Certara Stock We Don't?
The article discusses the unusually high options activity for Certara (NASDAQ: CERT) stock, specifically targeting the $15.00 strike price for the January 17, 2025 expiration. This surge in bullish options contracts, which typically represent a bet on a rising stock price, suggests that some options traders might be anticipating a significant upward movement in Certara's share value. The piece highlights that while options activity can indicate potential future price shifts, it's not a definitive prediction and should be considered alongside other investment research.
Certara (CERT) CHRO nets shares from RSU vesting and tax withholding
Certara, Inc.'s Chief Human Resources Officer, Rona Anhalt, reported routine equity compensation activity involving the vesting of restricted stock units (RSUs) on June 1, 2026. She exercised 7,147 shares, with 2,241 shares withheld to cover tax obligations at $5.82 per share. Following these transactions, Anhalt directly holds 16,789 shares of Common Stock, with the remaining RSUs scheduled to vest by June 1, 2027.
Certara (CERT) SVP Daniel Corcoran exercises RSUs; 12,103 shares withheld for taxes
Certara, Inc. Senior Vice President and General Counsel Daniel Corcoran exercised restricted stock units (RSUs) resulting in 22,830 shares of common stock. Concurrently, 12,103 shares were withheld at $5.82 per share to cover tax obligations related to the RSU vesting, with no open-market buying or selling reported. This transaction is a routine compensation-related event under the company’s 2020 Incentive Plan.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz Law Firm has initiated an investigation into potential claims on behalf of investors of Certara, Inc. (CERT). This alert suggests that the firm is looking into possible securities fraud or other illegal business practices that may have negatively impacted Certara shareholders. The investigation aims to determine if there were any misrepresentations or omissions that could warrant legal action.
Bronstein, Gewirtz & Grossman, LLC Encourages Certara, Inc. (CERT) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Certara, Inc. (NASDAQ: CERT) securities. This follows a significant drop in Certara's stock price after the company reported a 4% year-over-year decline in services revenue and a 14% decline in services bookings for Q1 2026, leading to a 19% stock price fall on May 11, 2026. The firm encourages affected investors to contact them for more information.
Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Certara, Inc. (CERT) following a significant drop in its stock price. This comes after Certara reported a 4% year-over-year decline in services revenue and a 14% decline in services bookings for Q1 2026, citing "softer performance from Tier 1 customers in MIDD services" and an exit from the regulatory business. Shareholders who purchased Certara securities are encouraged to contact the firm to learn more about potential claims.
Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
Certara (CERT) shares dropped significantly after the company's Q1 earnings report. Despite beating revenue estimates, the stock plummeted due to a weak full-year guidance that disappointed investors, indicating concerns about future growth.
Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Certara, Inc. (NASDAQ: CERT) after the company reported a decline in services revenue and bookings for Q1 2026, leading to an approximate 19% drop in its stock price. The firm is encouraging investors who purchased Certara securities to contact them to learn more about the investigation into the company's performance and disclosures.
CERT Earning Date, Earning Analysis and Earning Prediction
This article provides an in-depth analysis of Certara Inc. (CERT)'s recent and forecasted earnings, highlighting analyst predictions for revenue and EPS, and correlating them with stock price movements. It examines historical stock reactions to earnings reports and discusses key takeaways from the Q1 2026 earnings call, which focused on strong demand, strategic partnerships, and AI investments. The article aims to inform investors about potential opportunities based on CERT's financial performance and market sentiment.
